Pharmafile Logo

Reducing Carbon Footprint with Virtual Meetings – Perks of Virtual Medical Education

Discover how replacing in-person meetings with virtual alternatives can significantly cut carbon emissions and support environmental initiatives. Our latest video highlights the crucial role of virtual meetings in reducing the ecological impact of conferences. Join us in fostering a greener future!

Explore the environmental benefits of virtual meetings in our ninth video from the “Perks of Virtual Medical Education” series. Learn how shifting from in-person to virtual meetings can significantly reduce carbon emissions and support sustainability efforts.

9. The Environmental Footprint is Much Smaller with Virtual vs. In-Person Meetings The shift towards virtual meetings is not only a matter of convenience or cost but also a significant environmental decision. National and international in-person meetings often involve extensive travel that contributes to large carbon footprints. By incorporating virtual meetings, organizations can drastically cut down emissions associated with air travel and ground transportation. As the environmental movement gains momentum, and the pharmaceutical industry begins to embrace more sustainable practices, the preference for virtual participation continues to grow. Participants appreciate the option to engage from anywhere without the environmental cost of travel, and it is likely that such expectations will only increase in the future.

For more insights into how virtual meetings contribute to sustainability in medical education and beyond, visit our blog: https://www.impetusdigital.com/2020/09/17/top-10-reasons-why-virtual-collaboration-and-medical-education-will-persist-in-the-new-normal/

Enhance your sustainable engagement strategies with Impetus Digital:

Stay connected for more sustainable practices in medical education:

This content was provided by Impetus Digital

Company Details

 Latest Content from  Impetus Digital 

Navigating Regulatory Challenges – Top 10 Most Important Advisor Questions

This quick video covers #9 of our Top 10 Most Important Advisor Questions, shedding light on the complexities of local and national regulatory issues in the Pharma and Life Sciences...

Top-5 Trends in Virtual KOL Engagement

Register now for one of our upcoming webinars (February 26-28)

Engaging with Different Perspectives – Top 10 Most Important Advisor Questions

In this quick clip, we highlight a vital tip from our 'Top 10 Most Important Advisor Questions' – essential for enhancing your virtual collaboration strategies in Pharma and Life Sciences....

Patient Advocate Engagement: A Customer Story

Learn how our client executed a series of 3 virtual touchpoints with 5 rare disease patient advocates to:- Develop a better understanding of the current treatment landscape and lived patient...

Tailored Marketing Strategies for Pharma – Top 10 Most Important Advisor Questions

In this video, we explore another crucial aspect of advisor questions when developing your virtual advisory board touchpoints – a key component for success in today's diverse healthcare landscape. 7....

Trends in Virtual Collaboration

Join us for a look at the top-5 emerging virtual collaboration trends...

Advisor Questions on Potential Data or Knowledge Gaps

As part of our top 10 most important advisor questions that every brand team should keep in mind when designing virtual advisory board touchpoints, here's another one to keep in...

On a journey to diverse, inclusive, and more efficient rare disease trials

Although orphan drugs represent a sizeable portion of new drug approvals, most rare diseases still lack effective treatment. Even more so than for other conditions, rare disease management contains large care...

Versatility! Top 10 benefits of virtual advisory boards

Here's another great tip on why the benefits of virtual advisory boards are superior to in-person and hybrid advisory boards. #10. Versatility! Another major advantage of using a virtual platform...

Clinical Trials Investigator and Patient Engagement Planning: A Customer Story

In the early lead-up to our client’s multi-center Rare Disease Phase 3 Clinical Trial, they first conducted an internal engagement planning Longitudinal Expert Engagement Plan™ (LEEP™) to conduct an informal...